Study of the Effects of Food Formulations Containing Antioxidants, Prebiotic Fibers, and Oat Beta-glucans in Individuals at Risk of Metabolic Syndrome
Single-arm, Pre-Post Clinical Trial on the Effect of Food Formulations Containing Antioxidants, Prebiotic Fibers, and Oat Beta-glucans in Individuals at Risk of Metabolic Syndrome.
1 other identifier
interventional
40
1 country
1
Brief Summary
The goal of this clinical trial is to evaluate whether introducing specific functional foods into the diet of individuals at risk of developing metabolic syndrome leads to improvements in key metabolic and oxidative health parameters. The main questions it aims to answer are: Does the consumption of these functional foods reduce post-prandial glycemia? Does daily intake of these formulations improve other health indicators such as body weight, body composition, lipid profile, and oxidative metabolomic markers? The functional food formulations used in this study include: A blend of multifunctional ingredients derived from apple and grape by-products Added prebiotic fibers (inulin) Oat β-glucans Omega-3 fatty acids Participants will: Consume the assigned functional food formulations daily Attend regular clinic visits for physiological measurements and blood tests Undergo assessments of body composition, serum lipids, and serum metabolomics Primary Study Objective: Variation in post-prandial glycemia Secondary Objectives: Reduction in BMI Changes in body composition Changes in serum lipid profile Changes in serum oxidative-related metabolomics
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Feb 2026
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
February 1, 2026
CompletedFirst Submitted
Initial submission to the registry
March 20, 2026
CompletedFirst Posted
Study publicly available on registry
April 1, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 1, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
June 1, 2027
April 1, 2026
March 1, 2026
1 year
March 20, 2026
March 26, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Changes in postprandial glycemia
PHASE 1: from baseline to week 8; PHASE 2: from baseline to week 8
Secondary Outcomes (4)
Changes in BMI
PHASE 1: from baseline to week 8; PHASE 2: from baseline to week 8
Changes in body composition
PHASE 1: from baseline to week 8; PHASE 2: from baseline to week 8
Changes in serum lipid profile
PHASE 1: from baseline to week 8; PHASE 2: from baseline to week 8
Changes in serum oxidative related metabolomics
PHASE 1: from baseline to week 8; PHASE 2: from baseline to week 8
Study Arms (1)
Pre-post design
EXPERIMENTALStandard diet for 8 weeks, followed by the introduction of functional foods for an additional 8 weeks
Interventions
1. PHASE: Mediterranean diet for 8 weeks 2. PHASE: Mediterranean diet + functional foods for 8 weeks
Eligibility Criteria
You may qualify if:
- Age between 18 and 60 years
- Individuals who do not have metabolic syndrome
- Presence of abdominal circumference \>94 cm for men or \>80 cm for women, or a body mass index (BMI) between 25 and 34.9 kg/m², and at least two of the following parameters:
- Impaired glucose tolerance (IGT) (≥100 mg/dL), or borderline hypertension (systolic 120-139 mmHg, diastolic 80-90 mmHg), or mild hypercholesterolemia (200-239 mg/dL)
- Absence of any long-term pharmacological treatment for diabetes, hypertension, dyslipidemia, hyperuricemia, or other chronic conditions
You may not qualify if:
- Individuals with metabolic syndrome
- Continuous pharmacological treatments for dysmetabolic conditions
- BMI \<18.5 kg/m² or \>35 kg/m²
- Glycated hemoglobin (HbA1c) \> 6%
- Pregnancy
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Dr. Schär AG / SPAlead
- Bonvicini Cliniccollaborator
Study Sites (1)
Bonvicini Clinic
Bolzano, Bolzano, 39100, Italy
Related Publications (2)
Andrea Pichler, Serena Foria, Martina Magni, Veronica Marin, Manuel Pramsohler, Gaetano Cardone, Peter Robatscher, Silvano Ciani, Ombretta Polenghi, Virna Lucia Cerne, Michael Oberhuber, Comparative analysis of health-promoting nutrients in oat cultivars from Alpine production versus commercial origin, Journal of Cereal Science, Volume 127, 2026, 104351, ISSN 0733-5210, https://doi.org/10.1016/j.jcs.2025.104351. (https://www.sciencedirect.com/science/article/pii/S0733521025002504)
RESULTCardone G, Magni M, Marin V, Pichler A, Zatelli D, Robatscher P, Polenghi O, Cerne VL, Oberhuber M, Ciani S. Upcycling of By-Products from Autochthonous Red Grapes and Commercial Apples as Ingredients in Baked Goods: A Comprehensive Study from Processing to Consumer Consumption. Antioxidants (Basel). 2025 Jun 27;14(7):798. doi: 10.3390/antiox14070798.
PMID: 40722902RESULT
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SEQUENTIAL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 20, 2026
First Posted
April 1, 2026
Study Start
February 1, 2026
Primary Completion (Estimated)
February 1, 2027
Study Completion (Estimated)
June 1, 2027
Last Updated
April 1, 2026
Record last verified: 2026-03
Data Sharing
- IPD Sharing
- Will not share